Companies
DBN (Beijing Dabeinong)
2025 revenue ¥29.119 bn (+1.22%) but a -¥642M net loss (turnaround year); biobreeding corn/soy advancing across major ecological zones with ≥60% domestic promotion area targeted for 2026, and a South-American "1 team + 1 R&D + 1 JV + N partners" platform with soy entering commercialization in 2026.
- Country
- China
- Ticker
- SZSE:002385
GM insect-resistant corn
Drought-tolerant soy
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| crop-biotech | ✓ | ✓ | ✓ | ✓ |
Regulatorsusda-aphisepamoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | ¥29.119 billion | disc.static.szse.cn · pdf.dfcfw.com |
| Capacity | over 10 million tons annually for feed business | static.cninfo.com.cn · disc.static.szse.cn |
| Production site | 86 production bases for feed business across 29 provinces in China | static.cninfo.com.cn · disc.static.szse.cn |
| Certification | 2 National Key Laboratories, 4 Ministry of Agriculture and Rural Affairs key laboratories, 8 provincial research platforms, CNAS laboratory accreditation for biotechnology regulation, and membership in International Stewardship (ETS) | static.cninfo.com.cn · disc.static.szse.cn |
| Regulatory approval | 4 corn and 5 soybean trait products with domestic biosafety certificates; soybean trait products approved for cultivation in Argentina, Brazil, and Uruguay; DBN9004 approved for import in the EU | static.cninfo.com.cn · apps.fas.usda.gov · disc.static.szse.cn |
| Headcount | over 10,000 employees medium confidence | gabif.dbn.cn |
| Founded | 1993 | gabif.dbn.cn |
Independent sources: apps.fas.usda.gov · disc.static.szse.cn · gabif.dbn.cn · pdf.dfcfw.com · static.cninfo.com.cn
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Climate-resilient crops | crop-biotech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.